GoodRx Holdings (GDRX) Depreciation & Amortization (IS) (2019 - 2026)

GoodRx Holdings' Depreciation & Amortization (IS) history runs 8 years deep, the most recent figure standing at $21.8 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (IS) rose 4.21% year-over-year to $21.8 million; the TTM figure through Mar 2026 stood at $86.1 million (up 15.56% YoY), while the FY2025 annual figure was $85.2 million, up 22.55% from the prior year.
• Depreciation & Amortization (IS) came in at $21.8 million for Q1 2026 at GoodRx Holdings, down from $23.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (IS) ranged from a high of $43.6 million in Q4 2023 to a low of $11.4 million in Q1 2022.
• A 5-year average of $19.9 million and a median of $17.5 million in 2024 frame the typical range for Depreciation & Amortization (IS).
• Across the five-year window, Depreciation & Amortization (IS) jumped 180.74% in 2023 and tumbled 56.21% in 2024, its largest moves.
• GoodRx Holdings' Depreciation & Amortization (IS) stood at $15.5 million in 2022, then surged by 180.74% to $43.6 million in 2023, then sank by 56.21% to $19.1 million in 2024, then gained by 21.21% to $23.1 million in 2025, then dropped by 5.85% to $21.8 million in 2026.
• According to Business Quant data, Depreciation & Amortization (IS) over the past three periods registered $21.8 million, $23.1 million, and $21.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison